Antibody Engineering & Therapeutics (1)
Meet up with Albumedix at the 2017 Antibody Engineering & Therapeutics
Optimized Drug Dosing
Delivered by Albumedix and its partners, Veltis® technology optimizes drug dosing through its ability to increase half-life and tumor accumulation. These effects are achieved using recombinant human albumin and albumin variants implemented by genetic fusion or chemical conjugation to the drug candidate.
Veltis® offers drug developers a superior and highly versatile drug delivery platform that presents new opportunities to optimize the pharmacokinetics and efficacy of their peptides, proteins or small molecule drugs. The platform is based on recombinant human albumin and engineered albumin variants for optimized performance. Veltis® binds to a number of receptors, in particular the neonatal Fc receptor (FcRn) which, among other places, is found in endothelial cells.
Veltis® allows developers to design versions of their drug that can balance dose size and frequency in order to optimize peptide and protein tolerability and efficacy. This delivers drug differentiation benefits and supports patient compliance. In addition, the platform technology can improve patient quality of life by reducing the frequent dosing requirements associated with conditions such as diabetes and hemophilia.
Through its deep understanding of albumin’s biology, Albumedix has developed multiple albumin variants with modulated FcRn binding, as well as albumin variants with increased payload attachment.
Via genetic fusion or chemical conjugation the performance improvements of these Veltis® recombinant albumins can be transferred to active drug ingredients; leading to modulated drug plasma half-life and increased drug uptake or accumulation at diseased tissue compared to naked drug candidates, as well as payload optimization.
Veltis® albumin variants with significantly increased affinity to the FcRn are able to persist in the body significantly longer than native sequence human albumin. Linking active drug candidates to the modified albumin variants provides the potential to optimize dosing, efficacy and cost of systemically administered therapeutics.
The first drug to use Albumedix’s Veltis® technology was launched by GlaxoSmithKline in 2014 as Tanzeum® and Eperzan®. This is an albumin fusion of GLP-1 for the treatment of type 2 diabetes that allows for once weekly dosing.